Compare Edgewise Therapeutics Inc. Common Stock (EWTX) vs Navan Inc. Class A Common Stock (NAVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edgewise Therapeutics Inc. Common Stock vs Navan Inc. Class A Common Stock — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.32 (market cap $3.94B), while Navan Inc. Class A Common Stock trades at $23.66 (market cap $6.22B). The key difference: Navan Inc. Class A Common Stock is the larger of the two by market cap, and Edgewise Therapeutics Inc. Common Stock is more actively traded (810,104 versus 2,173,244). Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Navan Inc. Class A Common Stock for 6 Days on average.
| EWTX | NAVN | |
|---|---|---|
Market Cap | $3.94B | $6.22B |
Volume | 810,104 | 2,173,244 |
Sector | Health | Technology |
52-Week High | $48.35 | $30.58 |
52-Week Low | $14.89 | $8.51 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $3.48B | $5.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Navan (NAVN) trades at $23.9, up 1.44% on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported strong revenue growth of 35% year-over-year in Q2 2027 to $233 million, beating earnings expectations, yet remains unprofitable with a net income margin of -42.11%. Recent developments include the acquisition of BoomPop and a partnership with Engine to expand its AI-powered travel platform.
The outlook is mixed: unanimous analyst buy ratings and a $30.56 price target suggest 27.5% upside, driven by growth execution. However, high debt, persistent losses, insider selling, and ongoing legal investigations pose significant risks. The stock's valuation appears stretched given current profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Edgewise Therapeutics Inc. Common Stock
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →About Navan Inc. Class A Common Stock
Navan provides an AI-powered platform for business travel, payments, and expense management. Its tools support trip booking, policy controls, payment processing, expense reconciliation, and reporting.
Read more on NAVN →
